ESMO
hepatocellular carcinoma
gastric cancer
prostate cancer
Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer
Summary
The following ESMO Clinical Practice Guidelines have been recently updated with new treatment recommendations for the ESMO Clinical Practice Guidelines on Hepatocellular Carcinoma, Cancer of the Pancreas, Soft Tissue and Visceral Sarcomas, Cancer of the Prostate and Gastric Cancer.
Following the results of three studies, the management of advanced disease, systemic therapies for advanced hepatocellular carcinoma (HCC)-targeted first-line and second-line therapies have been updated. Lenvatinib received European Medicines Agency (EMA) approval in late 2018 and is associated with an ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) score of 4 [I, A; ESMO-MCBS v1.1 score: 4] Lenvatinib showed non-inferiority efficacy compared with sorafenib and can be considered in patients with advanced HCC without main portal vein invasion and with Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 as a front-line systemic treatment. Regorafenib is the standard of care for patients with advanced HCC who have tolerated sorafenib but progressed.
It is recommended in patients with well-preserved liver function and ECOG PS 0–1 [I, A; ESMO-MCBS v1.1 score: 4] for second-line treatment. Cabozantinib received EMA approval in late 2018 and is associated with an ESMO-MCBS score for 3 [I, A; ESMO-MCBS v1.1 score: 3]. It can be considered for patients who had progressive disease on one or two systemic therapies with well-preserved liver function and ECOG PS 0–1.....
Click for Source
ESMO, hepatocellular carcinoma, gastric cancer, prostate cancer,
